Prognostic Value of Troponin I in COVID-19 Patients
Alaa A. Ghaleb1, *, Ahmed Sadky2, Mohammed A. Meghaizel3, Shehab El Etriby4
Identifiers and Pagination:Year: 2021
First Page: 18
Last Page: 22
Publisher Id: TOCMJ-15-18
Article History:Received Date: 11/11/2020
Revision Received Date: 16/2/2021
Acceptance Date: 18/2/2021
Electronic publication date: 19/04/2021
Collection year: 2021
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Corona Virus Disease (COVID -19) patients present mainly with respiratory manifestations and viral pneumonia. The cardiovascular system presentation includes early signs of acute myocardial injury. Cardiac troponin I (cTnI) is a gold-standard biomarker for necrosis and myocardial risk assessment.
Aim of the work:
This study aimed to assess the prognostic value of cTnI in COVID-19 patients.
We report a prospective study that included 92 COVID-19 patients admitted to the El Helal Hospital, Sohag, Egypt. Upon admission, routine investigations including cTnI, chest Computed Tomography (CT), and Electrocardiogram (ECG) were carried out. The patients admitted to the intensive care unit (ICU) also had echocardiography.
More than half of the patients (55.4%) were admitted to ICU; cTnI level was elevated in 30 patients (58.8%), of whom 17 died (56.7%). There were statistically significant differences regarding the relation between cTnI level, D-dimer and the need for ICU admission and death (p=0.001).
We conclude that cardiac troponin I levels are a prognostic factor for ICU admission and mortality in COVID-19 patients.